Grifols Starts Manufacturing Its Immunoglobulin For The Treatment Of Covid-19

grifols1 777x400 1

Grifols announced yesterday that it has started production of hyperimmune immunoglobulin as a potential therapy for Covid-19. This makes it the first company to begin manufacturing anti-SARS-CoV-2 hyperimmune immunoglobulin, the first doses of which will be available in July. The aim is to integrate it into a clinical trial to evaluate its efficacy and subsequently begin the regulatory process for its approval.

This initiative is part of a multilateral agreement with various US public health agencies and institutions. But the Spanish producer of blood plasma-based products is also in talks to establish collaborations in Europe. In Spain, the clinical trial evaluating the effectiveness of intravenous immunoglobulin is continuing. The objective is to evaluate the action of neutralizing antibodies, as well as to determine the immunomodulatory potential of immunoglobulins as a treatment to block the cytokine storm that some of the most severe cases of Covid-19 present.

About the Author

The Corner
The Corner has a team of on-the-ground reporters in capital cities ranging from New York to Beijing. Their stories are edited by the teams at the Spanish magazine Consejeros (for members of companies’ boards of directors) and at the stock market news site Consenso Del Mercado (market consensus). They have worked in economics and communication for over 25 years.